Pharmacodynamic evaluation of YH4808 for Helicobacter pylori eradication in healthy subjects by 김춘옥 & 박민수
136https://tcpharm.org
ABSTRACT
YH4808 is a novel selective potassium-competitive acid blocker demonstrated to be safe and 
to have inhibitory effects against gastric acid secretion in previous studies. A randomized, 
open-label, multiple-dose, 3-treatment, 1-period, parallel design study was conducted to 
compare the Helicobacter pylori eradication rates and acid suppression capacities of three 
regimens in 60 healthy subjects with H. pylori-positive, and the potential of YH4808 to 
replace proton-pump inhibitors (PPIs) in standard regimens for H. pylori eradication. Group 
1 received YH4808, amoxicillin, and clarithromycin as a novel triple regimen, while Group 
2 received YH4808 and amoxicillin only, and Group 3 received esomeprazole, amoxicillin, 
and clarithromycin, as the standard triple regimen. H. pylori eradication rates were 85.0% for 
Group 1, 25.0% for Group 2, and 83.3% for Group 3. Relative response rate between Group 1 
and 3 was 1.02 (0.50–2.07; 95% CI, χ2 test p = 0.8881). Furthermore, the novel triple regimen, 
YH4808, amoxicillin, and clarithromycin, stably inhibited acid secretion and maintained 
a gastric pH greater than 4 or 5 for 24 hours, which was comparable to the pH range in the 
standard triple regimen. However, the onset times of the YH4808 regimens were earlier than 
that for the regimens using esomeprazole. There were no differences in the incidences or 
severity of adverse events among the three groups. Overall, the novel triple regimen was safe 
and well-tolerated. YH4808 could replace PPIs in standard triple regimens used for H. pylori 
eradication.
Trial Registration: ClinicalTrials.gov Identifier: NCT01921647
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INTRODUCTION
Helicobacter pylori is a bacterium parasite found in the mucous layer of the stomach. It secretes 
urease, which breaks down urea into ammonia to establish an environment conducive for 
its survival in the stomach [1]. H. pylori infection is a risk factor for various stomach diseases 
such as gastritis, gastric ulcers, duodenal ulcers, gastric cancer, and gastrointestinal cancer 




Received: Aug 19, 2020
Revised: Sep 16, 2020 
Accepted: Sep 20, 2020
*Correspondence to
Min Soo Park
Department of Clinical Pharmacology, 
Severance Hospital, Yonsei University College 
of Medicine, Department of Pediatrics, Yonsei 
University College of Medicine, 50-1 Yonsei-ro, 
Seodaemun-gu, Seoul 03722, Korea.
E-mail: minspark@yuhs.ac
Copyright © 2020 Translational and Clinical 
Pharmacology
It is identical to the Creative Commons 



















Hyeonsoo Park  1,2, Choon Ok Kim  1, Mikyung Kim  3, Yeji Lim  3,  
Woo Yul Lee  1,2, Sukyong Yoon  1,2, and Min Soo Park  1,4,*
1 Department of Clinical Pharmacology, Severance Hospital, Yonsei University College of Medicine, Seoul 
03722, Korea
2Department of Pharmacology, Yonsei University College of Medicine, Seoul 03722, Korea
3Clinical Development Department, R&D Division, Yuhan Corporation, Seoul 03722, Korea
4Department of Pediatrics, Yonsei University College of Medicine, Seoul 03722, Korea
Pharmacodynamic evaluation of 
YH4808 for Helicobacter pylori 
eradication in healthy subjects
Funding
This study was funded by Yuhan Corp, Seoul, 
Republic of Korea.
Reviewer
This article was reviewed by peer experts who 
are not TCP editors.
Conflict of Interest
-  Authors: Yeji Lim and Mikyung Kim are 
employees of Yuhan Corp, The authors did 
not play any major roles in the study design 
and data analysis.
- Reviewers: Nothing to declare
- Editors: Nothing to declare
Authors Contributions
Conceptualization: Lim Y, Kim M; Data 
curation: Oh ES, Kim CO, Park MS; Formal 
analysis: Park H, Oh ES, Kim Y, Park MS; 
Methodology: Oh ES, Kim CO, Lim Y, Kim M, 
Park MS; Project administration: Oh ES, Kim 
CO, Park MS; Writing - original draft: Park H, 
Park MS; Writing - review & editing: Park H, 
Kim CO, Lee WY, Yoon S, Park MS.
[2]. Physicians recommend H. pylori eradication for certain conditions such as atrophic 
gastritis, stomach ulcers, early stomach cancer, and low-grade MALToma [3]. If a patient 
suffering from gastric ulcers undergoes H. pylori eradication therapy, the gastric ulcer 
recurrence rate is reduced to 5% [4]. The first-line treatment for H. pylori is a triple regimen 
including a proton-pump inhibitor (PPI), clarithromycin, and amoxicillin, with an eradication 
rate of approximately 80% [5,6].
PPIs prescribed with antibiotics enhance antibacterial activity by increasing stomach pH and 
stabilizing antibiotics, which could be degraded by acidic conditions in the stomach. PPIs such 
as esomeprazole inhibit H+ and K+-ATPase by covalently binding to cysteines near ion-pathways. 
In addition, maintaining gastric pH above 4 or 5 enhances the antibacterial effects in H. pylori 
eradication therapies [7,8]. However, since PPIs are pro-drug forms of weak bases with pKa in 
the 3.8–4.9, they must be accumulated in the luminal surface of the stomach, where the pH is 
about 1.0, and transformed into activated forms [9]. Such modes of administration could have 
contrasting effects on different antibiotics. For example, amoxicillin and clarithromycin are 
unstable at pH < 2 in the stomach, while clarithromycin is likely to be degraded [10]. Similarly, 
the effects of the antibiotics can be slow before meals. Conversely, YH4808, developed by Yuhan 
Corporation, is a selective K+ competitive acid blocker (P-CAB), which competitively inhibits 
the proton pump through the potassium-dependent pathway. Since it is not a pro-drug, it does 
not require gastric acid activation; therefore, the onset of action is rapid so that it is effective. 
In addition, the polymorphism of the CYP2C19 genotype influences the H. pylori eradication rate 
of esomeprazole-based triple therapy. The eradication rate of H. pylori was significantly lower in 
EM than in non-EM [11,12]. However, the pharmacodynamic response of YH4808 is not highly 
affected by the CYP2C19 genotype [13].
In a previous study comparing the pharmacokinetics (PK) and pharmacodynamics (PD) of 
YH4808 and esomeprazole administered for 7 days to healthy subjects, YH4808 was superior 
to esomeprazole with regard to 24-hour gastric acid secretion inhibition and night acid 
secretion inhibition, in addition to tolerability and safety. In addition, the mean gastric pH 
over 24 hours was greater than 5 for YH4808, when compared with 4.3 for esomeprazole. 
In addition, the increasing pH after dosing seemed more rapid under YH4808 than under 
a PPI [13]. The results suggest that YH4808 could be used in place of PPIs in standard triple 
regimen for H. pylori eradication.
The PK drug interactions among YH4808, clarithromycin, and amoxicillin have been previously 
studied [14]. The aim of the present study was to evaluate and compare the PD responses of 
a potential novel triple or double treatment regimen for H. pylori eradication, which replaces 
esomeprazole with YH4808, with a standard triple regimen using esomeprazole.
METHODS
Study participants and design
The study was conducted at the clinical trials center, Severance Hospital, Yonsei University 
College of Medicine, Seoul, Korea. The study was registered in The ClinicalTrial.gov. 
(Registration number: NCT01921647). Healthy Korean volunteers aged 20–55 years, weighing 
55 kg or more, with a body mass index between 18.5 and 25.0 kg/m2 and who tested positive 
for H. pylori in a 13C -Urea breath test were enrolled in the present study. All participants 
provided written informed consent before being admitted into the study.
137https://tcpharm.org https://doi.org/10.12793/tcp.2020.28.e16
Pharmacodynamics of YH4808
The health of subjects was screened based on medical history, physical examination, a 12-lead 
electrocardiogram (ECG), vital signs, and laboratory tests.
Subjects with a potential history of allergic reaction to YH4808, esomeprazole magnesium, 
amoxicillin, and clarithromycin, or significant gastrointestinal disease, or history of major 
surgery were excluded. Heavy smokers (more than 10 cigarettes a day), habitual drinkers, and 
those who consume excessive caffeine were ineligible. Consumption of foods and beverages 
containing caffeine, alcohol, and grapefruit juice, as well as prescription drugs or oriental 
herbal medicines that could potentially interact with YH4808 was prohibited in the course of 
the study.
This study was a randomized, open-label, multiple-dose, 3-treatment, 1-period, parallel 
design study. Sixty healthy subjects were enrolled and randomly assigned to 3 groups, with 20 
subjects per group. Group 1 (YH+A+C) took 200 mg of YH4808 (Yuhan Corporation, Seoul, 
Korea), 1,000 mg of amoxicillin (Dongwha Pharm Corporation, Seoul, Korea), and 500 mg 
of clarithromycin (Abbott Korea Limited, Seoul, Korea) 30 minutes after meals BID for 7 days. 
Group 2 (YH+A) took 200 g of YH4808 and 1,000 mg of amoxicillin 30 minutes after meals 
forbid for 7 days, while Group 3 (N+A+C) took 20 mg of esomeprazole (Astrazeneca, Seoul, 
Korea), 100 mg of amoxicillin, and 500 mg of clarithromycin 1 hour before meals BID for 7 days.
H. pylori eradication rate and 24-hour pH monitoring
At least 14 days after the last dose of the 7-day administration, the 13C-urea breath test for 
H. pylori was performed again to evaluate the antibacterial effects of the three H. pylori 
eradication regimens adopted. The 13C-urea breath test yields high sensitivity and specificity 
for diagnosis of H. pylori infections [15].
Ambulatory 24-hour pH recording (Gastroesophageal reflux monitoring: pH and impedance 
Radu Tutuian and Donald O. Castell GI Motility online, 2006) was used to measure gastric 
pH continuously. A pH electrode was inserted into the stomach through the nasal cavity, and 
the lower end of the probe placed 5 cm below the lower end of the esophagus to measure pH 
with a constant time interval. The total pH measurement time was 1440 minutes (24 hours), 
and each measurement was obtained automatically every 5 seconds. The mean pH, which 
represented the averages of the measured for 1 minute, were obtained using the moving 
average method. In addition, to minimize variability through potential effects of posture 
on gastric pH, the subjects were instructed to maintain a supine position at bedtime from 
11:00 PM up to the following morning at 7:00 AM, and to maintain an upright position of 45 
degrees or greater from 7:00 AM to 11:00 PM.
Pharmacodynamic analysis
In the present study, PD analysis was conducted for the participants who took the medication 
and completed the gastric pH monitoring for 24 hours (7:00 AM on Day 1–7:00 AM on Day 
2, 7:00 AM on Day 7–7:00 AM on Day 8). As exploratory efficacy biomarker, the number and 
proportion of subjects with a negative 13C-urea breath test during the post-study visit were 
analyzed. The arithmetic mean and median of the gastric pH for 24 hours, the duration and 
proportion over which gastric pH was maintained at ≥ 4 or ≥ 5 for 24 hours were analyzed 
as PD parameters. Also, The areas under the effect curves (AUECs) for pH*time from 0 to 2 
hours and from 0 to 4 hours as well as pH*time from 0 to 24 hours were analyzed to evaluate 
early effect of the PPIs. The antibacterial effects of the three treatment groups were compared 




All subjects who had taken at least one dose of the prescribed medication were monitored 
for safety throughout the study. Adverse event monitoring, vital signs (temperature, blood 
pressure, pulse), laboratory tests (hematology, blood chemistry, and urinalysis), 12-lead 
ECG, and physical examination data were collected and evaluated as safety assessment 
parameters. Causality, frequency, and severity of adverse events were characterized based on 
the last dose for the different treatment groups.
Statistical analysis
All statistical analyses were conducted in SAS v9.2 (SAS Institute, Inc., Cary, NC, USA). The 
results of 13C-urea breath test at least 14 days after the last dose and the number and proportion 
of H. pylori negative subjects, as the exploratory efficacy biomarker were evaluated for each 
treatment group, and the differences between groups were analyzed using the χ2 test and the 
relative response rate (RR). In addition, the 24 hours gastric pH profiles were compared among 
treatment groups. Differences between Group 1 and Group 3, and Group 1 and Group 2, were 
tested using the independent t-test (inter-group difference of the pH change from Day 1 to 7) and 
the paired t-test (pH change from Day 1 to 7 in the same group). Further analyses were performed 
using the repeated Analysis of Variance as required. Differences in subject distribution were 
compared depending on whether the H. pylori was eradicated or not in each group.
Ethics approval
The present study was performed in compliance with the principles of the Declaration of 
Helsinki and Korean Good Clinical Practice regulations. The protocol was approved by the 
Institutional Review Board of Severance Hospital (approval number: 4-2013-0311).
RESULTS
Study subjects
In total, 60 healthy men age 23–52 years (32.2 ± 6.7 years) with a body mass index of 18.6–24.9 
kg/m2 (22.6 ± 1.8 kg/m2) were enrolled (Table 1); 2 subjects withdrew prior to dosing and were 
replaced. In the course of the study, 2 subjects dropped out and the remaining 58 subjects 
completed the study. In addition, only pH data from 57 participants were analyzed because 
pH values were all negative over 24 hours due to an unknown technical error. Negative pH 
values in the test subjects were excluded from the pH data analyses as they were considered 
to be noise or artifacts, temporary poor signals from the device, or were deemed not 
physiologically practical. The disposition of subjects is summarized in Fig. 1.
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Table 1. Demographic characteristics of subjects
Demographic variables Treatment (mean ± standard deviation) Total (n = 60) p-value*
Group 1 (n = 20) Group 2 (n = 20) Group 3 (n = 20)
Age (yr) 32.9 ± 7.2 32.5 ± 6.7 31.3 ± 6.4 32.2 ± 6.7 0.782
Weight (kg) 71.6 ± 7.0 70.5 ± 7.2 65.8 ± 7.0 69.3 ± 7.4 0.033
Height (cm) 177.0 ± 5.1 175.3 ± 4.8 172.5 ± 4.7 174.9 ± 5.1 0.022
BMI (kg/m2) 22.8 ± 1.5 22.9 ± 1.9 22.0 ± 2.0 22.6 ± 1.8 0.284
Smoking (yes/no) 5/15 8/12 6/14 19/41 0.692
Drinking (yes/no) 5/15 9/11 4/16 18/42 0.289
Caffeine (yes/no) 9/11 10/10 9/11 28/32 1.000
Group 1, YH4808 200 mg + Amoxicillin 1,000 mg + Clarithromycin 500 mg BID for 7 days; Group 2, YH4808 200 mg + Amoxicillin 1,000 mg BID for 7 days; Group 3, 
Esomeprazole 20 mg + Amoxicillin 1,000 mg + Clarithromycin 500 mg BID for 7 days.
BMI, body mass index.
*p-value for Fisher’s exact Test, Kruskal-Wallis Test.
Explolatory efficacy analysis
The results of the 13C-Urea Breath test conducted at least 14 days after the last repeated dose 
were as follows. After 7 d of repeated administration of the triple or double H. pylori regimens, 
the eradication rates of Group 1, Group 2, and Group 3 were 85.0%, 25.0%, and 83.3%, 
respectively (Fig. 2). The eradication rate of the Group 1 was 1.7% greater than that of the Group 
2 with an RR (95% CI) of 1.02 (0.50–2.07); (95% CI, χ2 test p = 0,8881). The eradication rate 



























Figure 1. Disposition of subjects. 
Group 1, YH4808 200 mg + Amoxicillin 1,000 mg + Clarithromycin 500 mg BID for 7 days; Group 2, YH4808 200 
mg + Amoxicillin 1,000 mg BID for 7 days; Group 3, Esomeprazole 20 mg + Amoxicillin 1,000 mg + Clarithromycin 
500 mg BID for 7 days. 
IP, investigational products. 
*Subjects requested withdrawal of consent; †A subject's pH value was excluded from the intra-gastric pH 
evaluation due to an unknown technical error, but the subject's result of 13C-Urea Breath test was included in the 



































Figure 2. H. pylori eradication results. 
Group 1, YH4808 200 mg + Amoxicillin 1,000 mg + Clarithromycin 500 mg BID; Group 2, YH4808 200 mg + Amoxicillin 
1,000 mg BID; Group 3, Esomeprazole 20 mg + Amoxicillin 1,000 mg + Clarithromycin 500 mg (Group 3) BID. 
Group 1 vs. Group 2; Group 1 vs. Group 3. The p-values obtained are based on the χ2 test.
(95% CI, χ2 test, p-value = 0.0001). In addition, the eradication rate of Group 3 was significantly 
higher than that in Group 2 (χ2 test, p-value = 0.0010) (Table 2).
Pharmacodynamic analysis
The median values of intra-gastric pH vs. time profiles for 24 hours following the 
administration of H. pylori treatment regimen (Day 7 and Day 1) are plotted in Fig. 3 and the 
mean values of pH monitored during H. pylori treatment regimens between groups and within 
groups are summarized in Table 3. There were no significant differences in mean pH values 
between Group 1 and Group 3 at Day 1 and at Day 7 (p = 0.2368 and p = 0.4138, respectively). 
In addition, pH values in Group 1 and Group 3 did not change significantly between Day 
1 and Day 7 (p = 0.0629). Conversely, there was a significant difference in the pH between 
Group 1 and Group 2 (p = 0.0096) value of Day 1, which was not observed at Day 7 (p = 0.0593). 
In addition, there was no significant difference in between Day 1 and Day 7 (p = 0.0822). Within 
each dose group, there was no significant difference in pH value between Day 1 and Day in Group 
1 (p = 0.1141); however, there were significant differences in Group 2 and in Group 3 (p = 0.0095 
and p = 0.0011 respectively).
The mean proportions of time over 24 hours period when pH was maintained ≥ 4 (%time 
pH ≥ 4) or ≥ 5 (%time pH ≥ 5) in the different treatment regimens on Day 1 and Day 7 were as 
follows. On Day 1, the %time pH ≥ 4 or %time pH ≥ 5 in the course of H. pylori treatment were 
85.9% and 79.6% in Group 1, 72.9% and 65.1% in Group 2, and 77.6% and 71.3% in Group 3, 
respectively. On Day 7, the proportions were 95.2% and 87.7% in Group 1, 88.5% and 77.4% in 
Group 2, and 95.8% and 90.2% in Group 3, respectively. The %time pH ≥ 4 or pH ≥ 5 between 
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Table 2. 13C-Urea breath test results after H. pylori treatment regimens
Groups Negative Positive Negative/Total RR (95% CI)*
Group 1 (n = 20) 17 3 0.85 -
Group 2 (n = 20) 5 15 0.25 3.40 (1.25–9.22)
Group 3 (n = 18) 15 3 0.833 1.02 (0.50–2.07)
Group 1, YH4808 200 mg + Amoxicillin 1,000 mg + Clarithromycin 500 mg BID for 7 days; Group 2, YH4808 200 
mg + Amoxicillin 1,000 mg BID for 7 days; Group 3, Esomeprazole 20 mg + Amoxicillin 1,000 mg + Clarithromycin 
500 mg BID for 7 days.
RR, relative response rate.
*Relative response rate of 2 groups; Group 1 as a reference.
Table 3. Summary of pharmacodynamic outcomes
Parameters Treatments
Group 1 (n = 20) Group 2 (n = 19) Group 3 (n = 18) Group 1–Group 2* Group 1–Group 3†
Mean pH‡
D1 6.03 ± 0.43 5.37 ± 0.94 5.66 ± 1.23 0.66 ± 0.23§ 0.37 ± 0.29
D7 6.21 ± 0.50 5.84 ± 0.66 6.34 ± 0.46 0.36 ± 0.19 −0.13 ± 0.16
D7–D1 0.17 ± 0.11 0.47 ± 0.12§ 0.68 ± 0.23§ −0.30 ± 0.17 −0.50 ± 0.25
Proportion of time (%)‡
pH ≥ 4
D1 85.9 ± 6.3 72.9 ± 17.9 77.6 ± 5.2 13.0 ± 4.2§ 8.28 ± 5.1
D7 95.2 ± 8.4 88.5 ± 12.0 95.8 ± 7.4 6.7 ± 3.3 −0.6 ± 2.6
D7–D1 9.3 ± 2.1§ 15.6 ± 2.7§ 18.2 ± 4.5§ −6.3 ± 3.4 −8.9 ± 4.8
pH ≥ 5
D1 79.6 ± 8.8 65.1 ± 22.5 71.3 ± 5.9 14.6 ± 5.4§ 8.3 ± 6.0
D7 87.7 ± 14.3 77.4 ± 16.8 90.2 ± 10.7 10.3 ± 5.0§ −2.5 ± 4.1
D7–D1 8.0 ± 3.2§ 12.3 ± 3.5§ 18.8 ± 4.9§ −4.3 ± 4.7 −10.8 ± 5.7
*ΔpH of 2 groups, Group 2 as a reference; †ΔpH of 2 groups, Group 3 as a reference; ‡Plus-minus values are means ± standard deviation in each group at Day 1 
and Day 7, means ± standard error in both inter/intra group comparisons; §p-value < 0.05 by independent or paired t-test
Group 1, YH4808 200 mg + Amoxicillin 1,000 mg + Clarithromycin 500 mg BID for 7 days; Group 2, YH4808 200 mg + Amoxicillin 1,000 mg BID for 7 days; Group 3, 
Esomeprazole 20 mg + Amoxicillin 1,000 mg + Clarithromycin 500 mg BID for 7 days.
the Group 1 and Group 2 was significantly different on Day 1 and on Day 7. However, there 
were no significant differences between Group 1 and Group 3 (Table 3).
The areas under the effect curve (AUECs) (pH*min) following oral administration of H. pylori 
treatment regimens are summarized in Table 4. The AUEC for pH-time was calculated (0 to 2, 
4, and 24 hours post-dose) to evaluate the starting point at which pH increased. AUEC (0–24 
hours) and AUEC (0–4 hours) on Day 1 in Group 1 were larger than that in Group 2. On Day 7, 
AUEC (0–4 hours) in Group 2 was as large as 94.5 pH*min, which was significantly larger than 
that in Group 1; however, there was no significant difference in AUEC (0–24 hours) among all 
the treatment regimens on Day 7.
Safety
Sixty participants were included in the safety assessment. Adverse events occurred in 22 
subjects (36.7%, 32 cases) in the present study. All the adverse events were mild and none 























Group 1 D1 (n = 20)
Group 2 D1 (n = 19)
Group 1 D7 (n = 20)





















Group 1 D1 (n = 20)
Group 3 D1 (n = 18)
Group 1 D7 (n = 20)
Group 3 D7 (n = 18)
Figure 3. Median 24-hour intra-gastric pH vs. time profiles following H. pylori treatment regimen administration. 
D1, 7:00 AM on Day 1–7:00 AM on Day 2; D7, 7:00 AM on Day 7–7:00 AM on Day 8. (A) YH4808 200 mg + Amoxicillin 
1,000 mg + Clarithromycin 500 mg BID (Group 1) vs. YH4808 200 mg + Amoxicillin 1,000 mg BID (Group 2); 
(B) YH4808 200 mg + Amoxicillin 1,000 mg + Clarithromycin 500 mg (Group 1) BID vs. Esomeprazole 20 mg + 
Amoxicillin 1,000 mg + Clarithromycin 500 mg (Group 3) BID.
16 cases). There were 18 adverse events that were suspected to have a causal relation with the 
prescribed medication, including 5 subjects (6 cases) in Group 1 for YH4808, amoxicillin and 
clarithromycin, 6 subjects (6 cases) in Group 2 for YH4808 and amoxicillin and 4 subjects 
(6 cases) in Group 3 for esomeprazole, amoxicillin and clarithromycin, with no significant 
differences between the groups in the number of the subjects who had adverse events 
suspected to have a causal relationship with the treatment (Fisher's exact test: p = 0.930). 
There was a total of 11 cases associated with gastrointestinal disorder. Headache was the 
most frequently reported adverse event and all adverse events were mild in severity. There 
were no serious adverse events in the present study and no clinically relevant changes were 
observed in vital signs, physical examination, ECG, and clinical laboratory tests, including 
serum gastrin.
DISCUSSION
The objective of the present study was to explore the potential of replacing esomeprazole, 
which is widely used as part of the standard triple regimen in H. pylori eradication therapies, 
with YH4808. Since the acid inhibition effect of esomeprazole has been demonstrated, We 
conducted the study to compare pharmacodynamic parameters of the standard regimen and 
the novel regimens. We enrolled healthy subjects who were H. pylori positive based on the 
13C-urea breath test and compared pharmacodynamic parameters and safety profiles among 
patients who received the standard triple regimen composed of esomeprazole, amoxicillin, 
and clarithromycin, a novel triple regimen using YH4808 in place of esomeprazole, and a 
novel double regimen consisting of YH4808 and amoxicillin.
Current clinical evidence suggests that PPIs (e.g., esomeprazole 40 mg QD or 20 mg BID), 
clarithromycin 500 mg BID, and amoxicillin 1,000 mg BID (or metronidazole 500 mg BID) 
administered for 14 days would achieve over 80% eradication, whereas the same regimen 
administered for 7 days achieves approximately 70% eradication [16,17]. In our studies, 
we used the same regimen for only 7 days, since the objective of the study was not to 
assess clinical efficacy of the treatments in patient populations but to compare short-term 
biomarkers between treatment regimens under similar conditions. The actual eradication 
rates were 85.0% (17 out of 20 subjects), 25.0% (5 out of 20 subjects), and 83.3% (15 out 
of 18 subjects) for the Group 1, Group 2, and Group 3, respectively. The eradication rates 
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Table 4. Area under the effect curve (pH*min) following oral administration of H. pylori treatment regimens (supplement)
Parameters Group 1 (n = 20) Group 2 (n = 19) Group 3 (n = 18) Group 1–Group 2* Group 1–Group 3†
AUEC (0–24 hr)‡
D1 8,687.9 ± 612.1 7,736.2 ± 1,351.7 8,153.3 ± 1,768.8 951.7 ± 333.1§ 534.6 ± 420.5
D7 8,938.3 ± 726.0 8,413.8 ± 948.0 9,125.5 ± 663.1 524.5 ± 269.5 −187.2 ± 226.5
D7–D1 250.4 ± 164.4 677.6 ± 173.9§ 972.2 ± 332.5§ −427.2 ± 239.1 −721.8 ± 359.6
AUEC (0–2 hr)‡
D1 327.2 ± 78.0 340.4 ± 125.6 361.1 ± 232.5 −13.2 ± 33.3 −33.8 ± 55.1
D7 710.4 ± 64.4 697.1 ± 98.7 769.2 ± 95.4 13.2 ± 26.6 −58.8 ± 26.2
D7–D1 383.1 ± 16.9§ 356.7 ± 26.4§ 408.1 ± 52.9§ 26.4 ± 31.0 −25.0 ± 53.2
AUEC (0–4 hr)‡
D1 916.8 ± 167.1 683.5 ± 220.1 875.4 ± 347.8 233.3 ± 62.4§ 41.4 ± 87.1
D7 1,415.5 ± 121.7 1,347.9 ± 226.3 1,510.0 ± 106.4 67.7 ± 57.8 −94.5 ± 37.3§
D7–D1 498.7 ± 30.6§ 664.3 ± 46.5§ 634.6 ± 77.2 −165.6 ± 55.2§ −135.9 ± 79.9
Group 1, YH4808 200 mg + Amoxicillin 1,000 mg + Clarithromycin 500 mg BID for 7 days; Group 2, YH4808 200 mg + Amoxicillin 1,000 mg BID for 7 days; Group 3, 
Esomeprazole 20 mg + Amoxicillin 1,000 mg + Clarithromycin 500 mg BID for 7 days.
*ΔAUEC of 2 groups, Group 2 as a reference; †ΔAUEC of 2 groups, Group 3 as a reference; ‡Plus-minus values are means ± standard deviation in each group on D1 
and D7, means ± standard error in inter/intra group comparisons; §p-value < 0.05 by independent or paired t-test.
of both triple regimens, Group 1 and Group 3, were much higher than expected based on 
literature, while there were no significant differences between the two regimens (95% 
CI of RR, 0.50–2.07). The double regimen did not yield a satisfactory response when 
compared with Group 1 or Group 3 (95% CI of RR, 1.25–9.22). We designed the novel double 
regimen with expecting a pharmacodynamic effect comparable to the triple regimens, but 
unfortunately, it did not.
Generally, the mean pH, %time pH ≥ 4 or pH ≥ 5 values were notably higher in Group 1 
than in Group 3 on Day 1 but only a little lower or similar on Day 7. Although there were 
no significant differences between the two regimens on Days 1 and 7, it is notable that 
Group 1 exhibited a trend where high pH was achieved quite rapidly with only one day of 
administration when compared with Group 3 (Fig. 4). The finding is consistent with YH4808 
properties, which is a selective K+ competitive acid blocker. In addition, it is not a pro-drug 
and does not require acid-driven activation, which is the case in numerous PPIs. Only the 
Group 1 did not exhibit significant difference in mean gastric pH for 24 hours between Day 
1 and Day 7 (independent or paired t-test, p-value > 0.05); i.e., YH could effectively increase 
gastric pH rapidly and maintain it at the relatively high levels even on Day 1. Similarly, there 
was no difference in AUEC (0–24 hours) between Day 1 and Day 7. In other words, Group 1 
regimen could increase gastric pH rapidly even on Day 1 to a level that could be achieved on 
Day 7, whereas the effect of the Group 3 regimen was not as rapid as that of Group 1
With regard to the safety profiles, adverse events, including gastrointestinal system-
associated symptoms, the symptoms in the Group 1 were the fewest when compared to the 
other groups, although there were no significant differences. Previous studies have also 
demonstrated that Group 1 regimen can be taken regardless of mealtime, which minimizes 
the chances of treatment failure due to poor medication compliance by a patient [18].
In conclusion, the results of the present study demonstrate that a novel triple regimen that 
adopts a P-CAB, namely YH4808, as opposed to a PPI is as effective as the conventional 
standard triple treatment regimen of esomeprazole, amoxicillin, and clarithromycin. The 
H. pylori eradication rates between Group 1 and Group 3 were similar with no significant 
differences. In addition, YH4808 increased gastric pH relatively rapidly and maintained it 
almost as effectively as esomeprazole, if not better. Overall, YH4808 could replace PPIs in 
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Figure 4. H. pylori treatment groups vs. Means of proportions of time under pH ≥ 4 or pH ≥ 5 (Day 7 and Day 1).  
Group 1, YH4808 200 mg + Amoxicillin 1,000 mg + Clarithromycin 500 mg BID; Group 2, YH4808 200 mg + Amoxicillin 
1,000 mg BID; Group 3, Esomeprazole 20 mg + Amoxicillin 1,000 mg + Clarithromycin 500 mg (Group 3) BID.
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